New Financing and Board Members for Positrigo
June 10, 2025
- This new financing round allows Positrigo to accelerate production and to focus on commercial roll-out in the US and Europe.
- Three new board members with extensive experience in medical technology, innovation and business management will strengthen Positrigo’s board of directors.
Positrigo, a Swiss based company developing nuclear medical devices to advance functional brain imaging, today announced the closing of a new financing round of 7 million CHF and the appointment of new board members. This financing was oversubscribed and brings reinforcement to Positrigo’s shareholding structure with lead investor HealthCap, a major European venture capital player in the life sciences space and Navivo, a venture capital fund supporting European tech companies in their global expansion. They were joined by existing shareholders and several family offices and individuals who are continuously supporting the company’s growth. The funds are instrumental to support production and accelerate the commercialization of the NeuroLF system – a dedicated brain Positron Emission Tomography (PET) device – which is the first product of its kind with market clearance in the US and EU.
Strong New Investor Group
“We are thrilled to have closed this financing round with a well-known and established European venture capital firm like HealthCap. Not only will it allow us to accelerate our commercial efforts in the US and EU but it is also testament for the strong business opportunity that lies ahead of us,” says Jannis Fischer, CEO and co-founder of Positrigo. “The NeuroLF system is used for the diagnosis of brain related disorders including brain tumors, epilepsy or movement disorders like Parkinson’s disease. However, the strongest demand for brain PET we see in the diagnosis of Alzheimer’s disease (AD) which is the most common form of dementia, accounting for ~70% of all dementias in those over 60. In 2023 there were over 55 million people worldwide living with dementia and it is predicted that individuals affected by AD will grow to 150 million in 2050. This investment allows us to capture this market opportunity by making brain PET imaging much more widely accessible than it is today.”
Max Odlander, partner at HealthCap, will represent the firm and support Positrigo by joining as a new board member.
“I am deeply impressed by what Positrigo accomplished already in a relatively short period of time and with limited resources. Beside the highly committed team, we believe that their imaging solution and the latest developments in the treatment of AD patients offers an exciting business opportunity. We are very excited to be part of it and to offer our support.”
Max Odlander, Partner at HealthCap and Positrigo Board Member
New Board Members
Beside Max Odlander, Positrigo is further strengthened by the appointment of two new independent board members. Mr. Didier Deltort is currently a Senior Advisor at several Venture Capital and Private Equity firms. With over 30 years of global experience in healthcare technology, he has held leadership roles at GE Healthcare, Zimmer Biomet, Boston Scientific, and HP Inc. At GE Healthcare, he spearheaded innovations in diagnostic imaging and patient monitoring, while at Zimmer Biomet he was overseeing the EMEA marketing, sales, and distribution of musculoskeletal products, including surgical robotics solutions. Dr. Ajit Singh is a partner and managing director at Artiman Ventures, based in Palo Alto, California. Prior to Artiman, he was the CEO of BioImagene – an Oncology diagnostics startup that was acquired by Roche in 2010. Earlier, he worked at Siemens for twenty years in the US and in Germany, the most recent ten years in global CEO roles for Siemens Oncology and Siemens Digital Imaging. Dr. Singh is an adjunct professor at the Stanford University School of Medicine, as well as a Trustee of the American Association for Cancer Research (AACR) Foundation.
Three existing board members do not stand for re-election. Prof. Alfred Buck (former Head of the NeuroPET program at University Hospital Zürich) and Dr. Max Ahnen (COO at Positrigo) are both co-founders and board members since inception and Dr Nicholas Verwilghen (Chief Investment Officer in 1741 Fund Solutions) joined the board during the last investment round. “I want to thank Prof. Buck, Dr. Ahnen and Dr. Verwilghen for their tremendous support as board members as they guided the company successfully through the transition from an R&D focused team to a commercial and customer facing organization,” says Urs Suter, Chairman of the Board of Directors. “We are very fortunate that we can still rely on their continued support and valuable insights.”
About Positrigo:
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo’s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. This award-winning product is the first device of its to gain market clearance in the US and EU.
About HealthCap:
HealthCap is a European venture capital firm investing globally in life sciences and has raised nine funds since 1996. HealthCap has backed and built more than 130 companies, taken more than 45 companies public, and completed numerous trade sales. The investment strategy focuses on precision medicine that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.